carotid artery disease
Conditions
Interventions
For patients that are randomised to the IMPROVE arm, the IMPROVE risk score will be provided as additional information for clinical decision-making on patient stratification for carotid revascularisat
Comparator: Patients randomised for the control arm (care-as-usual (CAU)) will be selected for revascularisation based on the guidelines for carotid interventions from the European Society for Vascula
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Recent (<30 days) stroke (modified Rankin scale =3) or TIAIpsilateral 30-99% NASCET carotid stenosis Life expectancy >5 years
Exclusion criteria
Exclusion criteria: Possible cardiac source of embolismClotting disorderMRI contra-indications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of ipsilateral ischemic stroke during 3-year follow-up and perioperative stroke and death. | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of other cardiovascular ischemic symptoms (any stroke, myocardial infarction, TIA)Quality of life questionnaire (EQ-5D-5L) questionnaireFunctional outcome (mRS)Costs (iPCQ, iMCQ, iVICQ) questionnairesIncremental cost-effectiveness ratio (ICER; see economic analysis)Number of hospitalizations and carotid revascularisation procedures (CEA, CAS). | — |
Countries
Netherlands
Contacts
Public ContactM.E. Kooi
Universiteit Maastricht
Outcome results
None listed